Table 4.
Comparison of clinical characteristics between patients who developed autoantibodies and patients who did not develop autoantibodies.
| Autoantibodies | |||
|---|---|---|---|
| Characteristics |
Negative (n = 48) |
Positive (n = 36) |
P |
| Age, median (range), y | 30 (16–61) | 29 (17–51) | 1.00 |
| Gender, no (%) | 0.82 | ||
| Male | 32 (66.7) | 25 (69.4) | |
| Female | 16 (33.3) | 11 (30.6) | |
| Primary disease, no (%)a | 0.67 | ||
| ALL | 20 (41.7) | 18 (50.0) | |
| AML | 26 (54.1) | 16 (44.4) | |
| Others | 2 (4.2) | 2 (5.6) | |
| Conditioning regimen, no (%)b | 1.00 | ||
| Myeloablative | 38 (79.2) | 29 (80.6) | |
| Intensified | 10 (20.8) | 7 (19.4) | |
| HLA typing, no (%) | <0.05 | ||
| Matched | 25 (52.1) | 28 (77.8) | |
| Mismatched | 23 (47.9) | 8 (22.2) | |
| Source of graft, no (%) | <0.01 | ||
| BM + PBSC | 27 (56.2) | 9 (25.0) | |
| PBSC | 21 (43.8) | 27 (75.0) | |
| GVHD prophylaxis, no (%)c | <0.01 | ||
| ATG based | 30 (62.5) | 10 (27.8) | |
| Non-ATG based | 18 (37.5) | 26 (72.2) | |
| Acute GVHD grade, no (%) | 0.46 | ||
| 0-I | 37 (77.1) | 25 (69.4) | |
| II-IV | 11 (22.9) | 11 (30.6) | |
| Chronic GVHD grade, no (%) | <0.001 | ||
| No | 34 (70.8) | 8 (22.2) | |
| Mild | 7 (14.6) | 4 (11.1) | |
| Moderate/Severe | 7 (14.6) | 24 (66.7) | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HLA, human leukocyte antigen; BM, bone marrow; PBSC, peripheral blood stem cell; GVHD, graft-vs.-host disease; ATG, antithymocyte globulin.
The other category included aplastic anemia, myelodysplastic syndrome, and lymphoma.
Myeloablative conditioning regimens include TBI (total body irradiation) + Cy (cyclophosphamide), Bu (busulfan)+ Cy, and Bu + Flu (fludarabine). Intensified conditioning regimens include TBI + Cy + etoposide, and Flu + cytarabine + TBI + Cy.
Non-ATG based GVHD prophylaxis include cyclosporine A (CsA), methotrexate (MTX), and mycophenolate mofetil (MMF). ATG based GVHD prophylaxis include CsA + MTX + MMF + ATG.